In Vivo and In Vitro Efficacy of Amodiaquine Monotherapy for Treatment of Infection by Chloroquine-Resistant Plasmodium vivax
- 1 March 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (3), 1094-1099
- https://doi.org/10.1128/aac.01511-08
Abstract
Amodiaquine retains efficacy against infection by chloroquine-resistant Plasmodium falciparum ; however, little information is available on its efficacy against infection by chloroquine-resistant Plasmodium vivax . Patients presenting to a rural clinic with a pure P. vivax infection that recurred after recent antimalarial treatment were retreated, this time with amodiaquine monotherapy, and the risk of further recurrence within 4 weeks was assessed. Of the 87 patients with pure P. vivax infection, 15 patients did not complete a full course of treatment, 4 of whom were intolerant to treatment. In the 72 patients completing treatment, 91% (63 of 69) had cleared their parasitemia within 48 h with no early treatment failure. Follow-up to day 28 or recurrent parasitemia was achieved for 56 patients (78%). The cumulative incidence of treatment failure by day 28 was 22.8% (95% confidence interval, 7.3 to 38%). The in vitro sensitivity profile was determined for a separate set of isolates from outpatients with pure P. vivax infection. The median 50% inhibitory concentration of amodiaquine was 11.3 nM (range, 0.37 to 95.8) and was correlated significantly with that of chloroquine (Spearman rank correlation coefficient, 0.602; P < 0.001) Although amodiaquine results in a rapid clinical response, the risk of recurrence by day 28 is unacceptably high, reducing its suitability as an alternative treatment of infection by chloroquine-resistant P. vivax in this region.Keywords
This publication has 45 references indexed in Scilit:
- Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparumMalaria Journal, 2008
- Determinants of In Vitro Drug Susceptibility Testing of Plasmodium vivaxAntimicrobial Agents and Chemotherapy, 2008
- Chloroquine-ResistantPlasmodiumvivax, Brazilian AmazonEmerging Infectious Diseases, 2007
- Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine–pyrimethamine in southern Papua, IndonesiaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2007
- Dihydroartemisinin-Piperaquine versus Artesunate-Amodiaquine: Superior Efficacy and Posttreatment Prophylaxis against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax MalariaClinical Infectious Diseases, 2007
- Relapses ofPlasmodium vivaxInfection Usually Result from Activation of Heterologous HypnozoitesThe Journal of Infectious Diseases, 2007
- Relapses ofPlasmodium vivaxInfection Result from Clonal Hypnozoites Activated at Predetermined IntervalsThe Journal of Infectious Diseases, 2007
- Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparisonThe Lancet, 2007
- Severe falciparum malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2000
- Clinical Pharmacokinetics and Metabolism of ChloroquineClinical Pharmacokinetics, 1996